Apjohn Ventures Fund, LP

Website Links

Description

Dr. Luderer has extensive experience in both the pharmaceutical industry and higher education. While in the pharmaceutical industry he held a series of executive positions at The Upjohn Company and Pharmacia. He has a global experience involving all phases of clinical research and pharmaceutical product development encompassing multiple IND and NDA filings. He served as Vice-President for Clinical Development and Vice-President for U.S. Medical Affairs during his last positions at Pharmacia.

The Michigan Growth Capital Symposium is the oldest university-based venture capital fair and the premier Midwest networking event for leaders in venture capital investment to connect with emerging growth companies actively searching for partners and funding. Since 2001, the Symposium has provided nearly 400 companies with the opportunity to present to investors. Roughly 70 percent of these have raised capital totaling $1.7 billion in investments and nearly 20 percent have realized successful exits.

MuciMed, Inc. was incorporated in Delaware in May, 2005 and the Company's business and research efforts are focused on developing and commercializing mucin proteins for the treatment of gastrointestinal (GI) disease. MuciMed's objective is to develop MUC17, a novel protein therapeutic, for the important treatment of mucositis, ulcerative colitis, and other colitides collectively known as Inflammatory Bowel Disease (IBD).

Charles has more than 30 years of experience in all phases of drug discovery, development and registration at Pharmacia Corporation and its predecessor companies Pharmacia & Upjohn and The Upjohn Company. During his career at these companies he held management positions of increasing responsibility in drug discovery and development. Most recently he served as Vice President, Product Development for CNS and Infectious Disease products with accountability for the worldwide development and registration of products in these therapeutic areas.

Sheri's responsibilities at the Apjohn Group include overseeing the evaluation and diligence processes associated with review of early stage life science opportunities. She has 30 years of multidisciplinary experience in the pharmaceutical industry, including the areas of quality assurance, pharmacovigilance, regulatory affairs and project management. Most recently, Sheri managed the worldwide development of new chemical entities and product line extensions, assuring that their successful development and registration aligned with corporate strategies and agreed timelines.

Companies nearby